- Aier Eye’s net income for the fiscal year reached 3.56 billion yuan, marking a 5.8% increase compared to the previous year, though it fell short of the estimated 3.7 billion yuan.
- Revenue grew by 3% year-over-year to 20.98 billion yuan, slightly below the expectation of 21.03 billion yuan.
- The company announced a final dividend of 16 RMB cents per share.
- Earnings per share (EPS) rose to 38.47 RMB cents, up from 36.31 RMB cents in the previous year.
- Current market sentiment includes 26 buy ratings, 6 hold ratings, and 2 sell ratings from analysts.
A look at Aier Eye Hospital Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Aier Eye Hospital Group is positioned for strong long-term growth and resilience in the ophthalmological services sector. With a high Growth score of 5, the company is expected to expand its operations and market presence significantly over the coming years. Coupled with a solid Resilience score of 4, Aier Eye Hospital Group demonstrates the ability to weather challenges and maintain stable performance.
Aier Eye Hospital Group also shows promising potential for dividends, as indicated by a score of 3. While the Value and Momentum scores are relatively lower at 2 each, the company’s core strengths lie in its growth prospects and ability to withstand market fluctuations. Overall, Aier Eye Hospital Group is well-positioned to capitalize on the growing demand for ophthalmological services, making it an attractive choice for long-term investors seeking exposure to this sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
